The University of Cambridge and Life Technologies have formed a collaboration to advance translational research studies in key disease areas such as cancer, diabetes and neurological disorders. Through
Kineta has been awarded a $6.8m subcontract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The grant is
Catalyst Pharmaceutical (Catalyst) has reported that a team of neuroscientists at The Feinstein Institute for Medical Research at North Shore-Long Island Jewish Health System (LIJ) has received a
Bio-Solutions has reported the negotiation of a supply agreement for its main product GreenEx with three African Countries. The agreement will include the turn key operation of the
ARmark Authentication Technologies (ARmark) and Colorcon have entered into an alliance in the development and introduction of ®mark On-Dose ID, an authentication technology that incorporates microscopic covert micro-tags
HealthSport has reported that its strategic manufacturing partner, SMI Manufacturing, has agreed to invest $10m into HealthSport. The investment is expected to accelerate HealthSport’s growth and strengthen its
Lubrizol has appointed Edward Campbell to its board of directors. Mr. Campbell is chairman, president and CEO of Nordson Corporation. Mr. Campbell spent 11 years in operating and
Mankind Pharma (Mankind) has received government of Himachal Pradesh’s approval to establish another facility in the state, stated the company. Reportedly, the company has installed its second unit
Trin Pharma has appointed Stefan Wohlfeil as a new CEO of the company, effective from October 6, 2009. Reportedly, Dr Stefan Wohlfeil previously held the position of chief
QuantRx has been developing a platform of point-of-care (POC) devices to facilitate diagnosis of critical metabolic markers, such as those associated with thyroid disease, malignant cancers, therapeutic drugs
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.